Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes

References

• Colombo AL, de Almeida Junior JN, Slavin MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017;17:e344–e356.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20:156–174.
   PubMedGoogle Scholar
• Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16:870–877.
   PubMed Web of Science ®Google Scholar
• Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.
   PubMed Web of Science ®Google Scholar
• Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–625.
   PubMed Web of Science ®Google Scholar
• Huang L, He H, Jin J, et al. Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/MSG and ICU criteria. BMC Infect Dis. 2017;17:209.
   PubMed Web of Science ®Google Scholar
• Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782–800.
   PubMed Web of Science ®Google Scholar
• Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47:1176–1184.
   PubMed Web of Science ®Google Scholar
• Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674–683.
   PubMed Web of Science ®Google Scholar
• Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest. 2002;121:1988–1999.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Harrington R, et al. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009–2013. Clin Infect Dis. 2018;67:727–735.
   PubMed Web of Science ®Google Scholar
• Dabas Y, Mohan A, Xess I. Serum galactomannan antigen as a prognostic and diagnostic marker for invasive aspergillosis in heterogeneous medicine ICU patient population. PLoS One. 2018;13:e0196196.
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341–347.
   PubMed Web of Science ®Google Scholar
• Shahid M, Malik A, Bhargava R. Bronchogenic carcinoma and secondary aspergillosis–common yet unexplored: evaluation of the role of bronchoalveolar lavage-polymerase chain reaction and some nonvalidated serologic methods to establish early diagnosis. Cancer. 2008;113:547–558.
   PubMed Web of Science ®Google Scholar
• Yan X, Li M, Jiang M, et al. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer. 2009;115:5018–5025.
   PubMed Web of Science ®Google Scholar
• Ohmagari N, Raad II, Hachem R, et al. Invasive aspergillosis in patients with solid tumours. Cancer. 2004;101:2300–2302.
   PubMed Web of Science ®Google Scholar
• Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol. 2011;49:S7–S12.
   PubMed Web of Science ®Google Scholar
• Georgiadou SP, Sipsas NV, Marom EM, et al. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52:1144–1155.
   PubMed Web of Science ®Google Scholar
• Lahmer T, Neuenhahn M, Held J, et al. Comparison of 1,3-β-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients. J Crit Care. 2016;36:259–264.
   PubMed Web of Science ®Google Scholar
• Úbeda-Iglesias A, Alonso-Romero L. Letter to the editor: comparison of 1,3-β-D-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients. J Crit Care. 2016;36:287–288.
   PubMedGoogle Scholar
• Schroeder M, Simon M, Katchanov J, et al. Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study. Crit Care. 2016;20:139.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Patterson TF, Slavin MA, et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis. 2015;60:713–720.
   PubMed Web of Science ®Google Scholar
• Ramos ER, Jiang Y, Hachem R, et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist. 2011;16:1049–1060.
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–540.
   PubMed Web of Science ®Google Scholar
• Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax. 1991;46:15–20.
   PubMed Web of Science ®Google Scholar